Drug Pattern Study on ARB at the Outpatient Department of Mohammad Hoesin General Public Hospital Palembang

Samantha Ferlin Boentara; Nita Parisa; Theodorus Parulian

doi:10.32539/mks.v54i4.18899

Drug Pattern Study on ARB at the Outpatient Department of Mohammad Hoesin General Public Hospital Palembang

Samantha Ferlin Boentara, Nita Parisa, Theodorus Parulian

Abstract

Backgrounds. Hypertension is a global health problem due to its increasing prevalence. Hypertension is a condition where there is a persistent increase in blood pressure exceeding 140/90 mmHg. Among the many choices of antihypertensive drug classes, ARB is one of the first-line drug classes for the treatment of hypertension. Inappropriate ARB administration can reduce the effectiveness of treatment and harm the patient. This study aims to determine the pattern of ARB use in hypertensive patients. Methods. This drug pattern study has been done on October – November 2021 at the Outpatient Department of Dr. Mohammad Hoesin Central Public Hospital Palembang. The sample was using the medical record data of all hypertensive patients period of July – December 2020 who met the inclusion criteria, with a total of 171 data. The data was processed by using the SPSS v25 and presented in the form of a table with a descriptive explanation referring to the research variables. Results. This study found that the prevalence of ARB use was 59.0% with the highest was in male (30.4%) and age group 41-60 years (29.2%). The most widely used ARB is candesartan (94.0%) at a dose of 16 mg (52.6%), frequency once a day (97.9%) and duration more than one month (93.7%). The drug prescribed to the patient mostly didn’t have interaction with ARB (33.0%). Conclusions. The prevalence of ARB administration is high in hypertensive patients (59.0%) with the most commonly used ARB is candesartan (94.0%).

Keywords

hypertension, ARB, drug pattern study

References

Grossman S, Porth CM. Porth’s Pathophysiology: Concepts of Altered Health States. 9th ed. Philadephia: Wolters Kluwer Health, Lippincott Williams & Wilkins.; 2014. 773–780 p.

Mills KT, Stefanescu A, He J. The Global Epidemiology of Hypertension. Nat Rev Nephrol [Internet]. 2020;16(4):223–37. Available from: http://dx.doi.org/10.1038/s41581-019-0244-2

Kemenkes. Laporan_Nasional_RKD2018_FINAL.pdf [Internet]. Badan Penelitian dan Pengembangan Kesehatan. 2018. p. 198. Available from: http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf

Rilantono LI. 5 Rahasia Penyakit Kardiovaskular (PKV). 2nd ed. Rahajoe AU, Karo-Karo S, editors. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2013. 235–248 p.

Delacroix S, Chokka RG. Hypertension: Pathophysiology and Treatment. J Neurol Neurophysiol. 2014;05(06).

Yogiantoro M. Hipertensi Esensial. In: Buku ajar ilmu Penyakit Dalam Jilid I. 4th ed. Jakarta: Balai Penerbit FKUI; 2006. p. 610–4.

AlDrabah E, Irshaid Y, Yasein N, Zmeili S. Prescription pattern of antihypertensive drugs in Family Practice Clinics at Jordan University Hospital. Med Sci | Int Med J. 2013;2(1):469.

Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison’s Principles of Internal Medicine. 16th ed. New York: McGraw-Hill Education; 2005.

McCance KL, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 7th ed. St. Louis: Mosby Elsevier; 2014. 1200–1208 p.

Alkaabi M, Rabbani S, Rao PM, Ali S. Prescription pattern of antihypertensive drugs: An experience from a secondary care hospital in the United Arab Emirates. J Res Pharm Pract. 2019;8(2):92.

Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens [Internet]. 2015;22(1):1–8. Available from: http://dx.doi.org/10.1186/s40885-016-0042-0

Bell K, Twiggs J, Olin BR. Hypertension : The Silent Killer : Updated JNC-8 Guideline Recommendations. In: Continuing Education. Alabama Pharmacy Association; 2015. p. 1–8.

Katzung BG. Basic & Clinical Pharmacology. 14th ed. New York: McGraw-Hill Education; 2018.

Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 6th ed. Philadephia: Wolters Kluwer; 2015.

Craig CR, Stitzel RE. Modern Pharmacology With Clinical Applications. 6th ed. Philadephia: Lippincott Williams & Wilkins; 2004.

Shukrala F, Gabriel T. Assessment of prescribing, dispensing, and patient use pattern of antihypertensive drugs for patients attending outpatient department of hiwot fana specialized university hospital, harar, eastern Ethiopia. Drug Des Devel Ther. 2015;9:519–23.

Abraham HMA, White CM, White WB. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. Drug Saf. 2015;38(1):33–54.

Kim SH, Shin DW, Kim S, Han K, Park SH, Kim YH, et al. Prescribing patterns of antihypertensives for treatment-naïve patients in South Korea: From Korean NHISS claim data. Int J Hypertens. 2019;2019.

Xie Q, Hao CM, Ji L, Hu D, Zhu T, Li X, et al. ACEI/ARB underused in patients with type 2 diabetes in Chinese population (CCMR-3B study). PLoS One. 2015;10(2):1–12.

Rudolph UM, Enners S, Kieble M, Mahfoud F, Böhm M, Laufs U, et al. Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. J Hum Hypertens [Internet]. 2021;35(10):903–11. Available from: http://dx.doi.org/10.1038/s41371-020-00425-z

Fox K, McCormack T, Purcell H. Are all angiotensin receptor blockers the same ? Br J Cardiol [Internet]. 2010;17. Available from: http://bjcardio.co.uk/files/uploads/2010/05/supp/takeda-supplement-oct-no-pi-wm.pdf

FDA. ATACAND Prescribing Information. HIGHLIGHT OF PRESCRIBING INFORMATION. U.S Food and Drug Administration; 2015.

Husain A, Azim MS, Mitra M, Bhasin PS. A review on Candesartan: Pharmacological and Pharmaceutical Profile. J Appl Pharm Sci. 2011;1(10):12–7.

Bönner G, Fuchs W. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension. Curr Med Res Opin. 2005;21(6):935–40.

Sweetman S. Martindale The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.

FDA. DIOVAN Prescribing Information. U.S Food and Drug Administration; 2011.

Siddiqui N, Husain A, Chaudhry L, Alam MS, Mitra M, Bhasin PS. Pharmacological and Pharmaceutical Profile of Valsartan: A Review. J Appl Pharm Sci. 2011;1(4):12–9.

FDA. MICARDIS Prescribing Information. U.S Food and Drug Administration; 2011.

FDA. AVAPRO Prescribing Information. U.S Food and Drug Administration; 2016.

Husain A, Mitra M, Bhasin PS. A Review of Pharmacological and Pharmaceutical Profile of Irbesartan. Pharmacophore. 2011;2(6):240–50.

Rahmawati F, Handayani R, Gosal V. Kajian Retrospektif Interaksi Obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta. Maj Farm Indones. 2006;17(4):177–83.

Gitawati R. Jurnal Interaksi Obat. J Interak Obat. 2008;18(4):175–84.

Baxter K. Stockley’s Drug Interactions. 9th ed. London: Pharmaceutical Press; 2010.

DOI: https://doi.org/10.32539/mks.v54i4.18899